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Introduction
Osteoarthritis (OA) is a major cause of functional impair-
ment and disability among the elderly [1], yet current ther-
apies predominantly target symptoms rather than
providing prevention or curative treatment. Animal models
of OA have been used extensively for studying the patho-
genesis of cartilage degradation as well as the efficacy of
potential therapeutic interventions [2]. However, most of
the currently available models only approximate the mech-
anisms underlying the human disease. Although several
animal species – such as mice, Syrian hamsters, guinea
pigs, and nonhuman primates – can develop spontaneous
OA, the development of disease in these models is slow;
typically, more than 9 to 12 months is required for signifi-
cant cartilage erosion to occur [2]. Consequently, these
spontaneous models are cumbersome and time-consum-
ing to use in arthritis research and drug development.
Transgenic mice models have been of great help in clarify-
ing the role of numerous pathogenic factors (matrix metal-
loproteinases, transforming growth factor β, nitric oxide) in
the development of OA, yet these models may not be
applicable for studies testing the therapeutic potentials of
chondroprotective agents [3,4]. Surgically induced joint
damage has also been used extensively as a model of OA,
though this condition more nearly approximates a trau-
matic form of OA than it does the natural, spontaneously
CTX-I = collagen type I fragments; CTX-II = collagen type II degradation products; ELISA = enzyme-linked immunosorbent assay; OA = osteoarthri-
tis; OVX = ovariectomized; SD = standard deviation; SEM = standard error of the mean; SERM = selective estrogen receptor modulator.
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Abstract
We aimed to assess the effect of ovariectomy on cartilage
turnover and degradation, to evaluate whether ovariectomized
(OVX) rats could form an experimental model of
postmenopausal osteoarthritis. The effect of ovariectomy on
cartilage was studied using two cohorts of female
Sprague–Dawley rats, aged 5 and 7 months. In a third cohort,
the effect of exogenous estrogen and a selective estrogen
receptor modulator was analyzed. Knee joints were assessed
by histological analysis of the articular cartilage after 9 weeks.
Cartilage turnover was measured in urine by an immunoassay
specific for collagen type II degradation products (CTX-II),
and bone resorption was quantified in serum using an assay
for bone collagen type I fragments (CTX-I). Surface erosion in
the cartilage of the knee was more severe in OVX rats than in
sham-operated animals, particularly in the 7-month-old cohort
(P = 0.008). Ovariectomy also significant increased CTX-I
and CTX-II. Both the absolute levels of CTX-II and the relative
changes from baseline seen at week 4 correlated strongly
with the severity of cartilage surface erosion at termination
(r = 0.74,  P < 0.01). Both estrogen and the selective
estrogen receptor modulator inhibited the ovariectomy-
induced acceleration of cartilage and bone turnover and
significantly suppressed cartilage degradation and erosion
seen in vehicle-treated OVX rats. The study indicates that
estrogen deficiency accelerates cartilage turnover and
increases cartilage surface erosion. OVX rats provide a useful
experimental model for the evaluation of the
chondroprotective effects of estrogens and estrogen-like
substances and the model may be an in vivo representation
of osteoarthritis in postmenopausal women.
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evolving form [5]. Thus, there is an apparent need for an
OA model that directly mimics a human form of the
disease and at the same time provides a convenient
methodological tool for preclinical investigations.
Development of such a generally applicable and conve-
nient animal model of OA is complicated by the fact that
our current understanding of the pathophysiology of the
human disease is incomplete. However, one factor
thought to affect the regulation of cartilage turnover is
estrogen. The putative role of estrogens is corroborated
by the fact that the prevalence of OA is higher in post-
menopausal women than in men [6–8]. Furthermore, the
recent finding that ovariectomized (OVX) cynomolgus
monkeys show OA-like pathological changes within articu-
lar joints [9], as well as the chondroprotective effects of
hormone replacement therapy proposed by some epidemi-
ological observations [10,11], also argues for the involve-
ment of estrogen deficiency in female OA.
The present study was designed to evaluate the role of
estrogen in regulating cartilage turnover, by investigating
the effects of ovariectomy on cartilage. Histological analy-
sis of the knee joint was used to assess the pathological
changes of the articular cartilage erosions. Furthermore,
the effects of cessation of endogenous estrogen produc-
tion on bone and cartilage turnover were assessed using
biochemical markers of collagen type I and II degradation
(CTX-I and CTX-II). An additional aim was to clarify
whether OVX rats could provide a useful model of post-
menopausal OA for future preclinical studies assessing
the chondroprotective effects of exogenously adminis-
tered estrogens and estrogen-like substances such as
selective estrogen receptor modulators (SERMs).
Materials and methods
Animals and study design
Sprague–Dawley rats (Crl:CD®(SD)IGS.BR) obtained
from Charles River Laboratories, Kisslegg, Germany, were
used. Experiments were approved by the Experimental
Animal Committee, Danish Ministry of Justice (Slotsholms-
gade 10, DK-1216, Denmark) (approval number
2002/561-566) and were done in accordance with the
European Standard for Good Clinical Practice. The
animals were maintained at the Animal Research Facilities
at Nordic Bioscience for 1 month before the start of exper-
iments. They were housed, two per cage, in a room main-
tained at 20°C with a 12-hour/12-hour light/dark cycle
and given food (Altromin 1234, Lage, Germany) and
Milli Q water (Millipore, Glostrup, Denmark) ad libitum.
Study of age-related changes in cartilage turnover in
rats
To assess age-related changes in cartilage turnover, we
measured the creatinine-corrected excretion of CTX-II (for
details see below) in the urine of six male and six female
rats sampled at 1, 2, 3, 6.5, and 9.5 months of age. Urine
samples were obtained as spot samples by placing the
rats in a metabolic cage for 30 to 60 min and waiting for
them to urinate.
Study of the effect of ovariectomy in OVX rats
For these studies, two cohorts of 20 virgin female
Sprague–Dawley rats were used. At the start of the study
they were either 5 months old (cohort A) or 7 months old
(cohort B). At this baseline, body weight was determined
and the animals were randomly stratified into two groups to
undergo either bilateral ovariectomy using a dorsal
approach or a standard sham operation under general anes-
thesia induced by Hypnorm-Dormicum (1 part Hypnorm® +
1 part Dormicum® + 2 parts sterile deionized water; dose
0.2 ml/100 g body weight). During the 9 weeks of follow-
up, body weight was determined weekly; urine samples
were obtained at baseline and weeks 2, 4, 6, and 9 after
ovariectomy. At study termination, the knees were isolated
and kept in 4% formaldehyde until further quantification of
surface erosion in the articular cartilage by histological
measurements as outlined below.
Study of the effect of exogenous estrogen and SERM
For this purpose, a cohort of 60 5-month-old virgin female
Sprague–Dawley rats was included. At baseline, body
weight was determined and the animals were randomly
stratified into five groups with 12 rats in each group. One
group was subjected to sham operation and the remaining
four groups were ovariectomized as described above. The
four equal groups received treatment either with the
vehicle (50% Propylene Glycol [Unikem, Copenhagen,
Denmark], 0.075 M NaCl), or with 17α-ethinylestradiol
(E-4876, Sigma, St Louis, MO, USA) (0.1 mg/kg per day),
or with the SERM (–)-cis-3,4-7-hydroxy-3-phenyl-4-(4-(2-
pyrrolidinoethoxy)phenyl)chromane [12] given as an oral
suspension in the vehicle from day 1 by gavage 5 days a
week for 9 weeks, in either a low or a high dose (0.2 or
5 mg/kg per day, respectively). Animals were weighed and
sampled for spot urine and serum at regular intervals. At
study termination, knee joints were prepared for histology
as described below.
Materials and buffers
All chemicals were analytical grade and purchased from
either Sigma or Merck (Darmstadt, Germany). Peptides,
from Chimex Ltd (St Petersburg, Russia), were >95%
pure. Cell-culture reagents were obtained from Life Tech-
nologies, UK. The buffers used in the immunoassays have
been described elsewhere [13; P Qvist and colleagues,
unpublished].
Histology
After careful dissection, the knees were decalcified for 3
to 4 weeks in 10% formic acid, 2% formaldehyde. The
decalcified knee joints were cleaved along the medial col-R171
lateral ligament into two sections and embedded in paraf-
fin. Coronal sections were then cut at three different
depths (0, 250, and 500 µm) from the medial collateral lig-
ament. Each section was stained in Toluidine blue and the
section that comprised the most load-bearing region were
used for measurements. The histological sections were
assessed by a blinded observer.
In a preliminary study, we evaluated apparent histological
features as well as applicable assessment methods for
quantifying pathological changes in the knee joints. The
previously described Mankin and Colombo score systems
are used in analyzing known OA models such as the
guinea pig, and may not fulfil the criteria for a reliable
scoring system in this OVX rat model [14]. In the prelimi-
nary study, we analyzed OVX and sham-operated rats by
the Colombo method and found that erosion was the
feature most readily influenced by the ovariectomy in the
OVX rats in comparison with the sham-operated rats. In
order to simplify evaluation protocols and increase the
robustness of the scoring system, we found it more repro-
ducible to concentrate evaluation on surface erosion as
the main feature of cartilage damage. Exact numerical
values were obtained by measuring the length of the
erosion surface and dividing it by the total cartilage
surface. This approach enabled us to quantify erosion in
exact numerical values instead of scores relying on the
observer. Furthermore, it relates to a feature that is directly
relevant to development of OA lesions. We therefore
decided to keep the analysis simple and focus on surface
erosion.
RatLaps ELISA to assess bone resorption
The RatLaps ELISA (Nordic Bioscience Diagnostics A/S,
Herlev, Denmark) measures collagen type I C-telopeptide
degradation products (CTX-I) using a specific monoclonal
antibody in a competitive ELISA form [P Qvist and col-
leagues, unpublished]. The assay is applicable for mea-
surement of both urine and serum samples, but only serum
samples were assessed in this study. All serum samples
measured in the assay were from animals that had been
fasting for at least 6 hours prior to the sampling. Briefly,
the assay is performed by incubating a biotinylated form of
a synthetic peptide representing the C-telopeptide
epitope EKSQDGGR. This is followed by addition of
sample and primary antibody and after overnight incuba-
tion the amount of bound antibody is made visible using a
peroxidase-labeled secondary antibody and a chro-
mogenic peroxidase substrate. The concentrations in the
samples were determined from the construction of a cali-
bration curve based on the measurement of synthetic
peptide standards. Intra-assay and interassay variations
were 6.9% and 10.4%, respectively. All samples were
measured in duplicate and samples from the same animal
were included on the same microtiter plate. Three genuine
control samples were included on each microtiter plate to
verify performance, and samples were remeasured if the
coefficients of variation exceeded 15% or if any of the
control samples measured more than 20% off the prede-
termined value.
CartiLaps ELISA to assess cartilage turnover
Monoclonal antibody mAbF46 specific for collagen type II
C-telopeptide fragments (CTX-II) was used in a competi-
tive ELISA format developed for measurement of CTX-II in
urine samples (CartiLaps ELISA, Nordic Bioscience Diag-
nostics A/S) [13]. The assay was performed by first incu-
bating biotinylated collagen type II C-telopeptide-derived
peptide (EKGPDP) on a streptavidine microtiter plate, and
then the sample as well as the primary antibody were
added. After overnight incubation, the plates were washed
and a peroxidase-labeled secondary antibody was added,
followed by a chromogenic peroxidase substrate. The con-
centrations of CTX-II (µg/l) were standardized to the total
urine creatinine (mmol/l) (JAFFA method; Hoffmann-La
Roche, Basel, Switzerland) giving concentration/creati-
nine (µg/mmol). The precision of the assay was 7.1% and
8.4% for intra-assay and interassay variations, respec-
tively. Assay performance and quality assurance were
treated as described above for the CTX-I assay.
Statistical analysis
Means and SDs were calculated using parametric statis-
tics. Differences between groups were assessed with the
Mann–Whitney  U-test for unpaired observations. The
association between the biomarkers and the histology
data was calculated using Spearman’s rank correlation.
Results
Age-related changes in cartilage turnover
Cartilage turnover occurs predominantly in the articular
cartilage and in the ectopic growth plate during skeletal
growth. We first wanted to assess cartilage turnover levels
in normal Sprague–Dawley rats, to identify the age at
which the turnover stabilizes.
Normal levels of collagen type II turnover were assessed in
Sprague–Dawley rats by obtaining samples from six male
and six female rats, each tested at 1, 2, 3, 6.5, and
9.5 months of age. Creatinine-corrected urinary CTX-II
levels are shown in Fig. 1. This marker decreased substan-
tially over the investigated age range in both sexes. This
decline was most pronounced in animals younger than
3 months of age, implying that older animals should be
used in studies of articular cartilage turnover to minimize
contribution from the growth plate.
Baseline characteristics and changes in body and
uterus weight
Two cohorts each comprising 20 female Sprague–Dawley
rats were used to assess the effect of ovariectomy on car-
tilage turnover and erosion. The animals were aged
Available online http://arthritis-research.com/content/6/2/R1695 months (cohort A) or 7 months (cohort B) at the start of
the study. Two animals in cohort A and three in cohort B
died at the start of the study because of hypersensitivity to
general anesthesia or extensive hematoma that occurred
during blood sampling. The baseline characteristics of the
rats included in the study are shown in Table 1.
Ovariectomy induced significant weight gain in the
animals, reaching 27% and 17% in the 5- and 7-month-
old cohorts, respectively, after 9 weeks (Table 1). The cor-
responding changes in the sham-operated groups were
10% and 6%, respectively. At study termination, the wet
weight of the uterus was measured. Ovariectomy induced
significant regression of the uterus in both cohorts, com-
pared with age-matched sham-operated animals (Table 1).
Sixty 5-month-old rats were used to study the effect of
estrogen and SERM administration (cohort C; Table 2).
Two animals from the sham-operated group and one each
from the estrogen and low-dose SERM groups died
during surgery at the start of the study. At baseline, there
were no significant differences in body weight (Table 2) or
in levels of CTX-I and CTX-II in the five study groups (data
not shown). At study termination, after 9 weeks of treat-
ment, uterus weights in the SERM-treated groups were
slightly higher than in the vehicle-treated group. The sham-
operated and estrogen-treated groups had significantly
higher uterus weights, which is in accord with the
uterotropic effects of estrogen, and the uterus weights in
the estrogen group were lower than in the sham-operated
group (Table 2). Body weights were significantly
decreased in the OVX estrogen-treated and OVX high-
dose SERM-treated rats at the end of the experiment in
comparison with the OVX vehicle-treated rats (Table 2).
Cartilage erosion
In a preliminary study, we evaluated histological assess-
ment methods to find out which were best suited to
assess articular cartilage damage in ovariectomy. The pre-
viously described scoring systems by Mankin and
Colombo are used for analyzing guinea pigs, which have a
different pathology and histological appearance [14]. They
did not appear to fulfill the criteria for a reliable scoring
system in this rodent model. We scored 12 rats (6 OVX,
6 sham-operated) according to Mankin and Colombo’s cri-
teria by assessing the cartilage surface (loss of superior
layer, fibrillation, and erosion), the cartilage matrix (territor-
ial loss, interterritorial loss, and vascularization), and the
chondrocytes (loss, disorganization, and clones). All nine
parameters were higher in the OVX rats than in the sham-
operated rats, but erosion, especially, was increased more
than threefold (data not shown). In order to simplify the
evaluation procedure and increase the robustness of the
scoring system, we found it more reproducible to assess
the most prominent feature of the disease, surface
erosion. This approach also results in a numerical value for
the surface erosion, expressed as a percentage of the
total cartilage surface, instead of scores determined sub-
jectively by the observer.
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Figure 1
Normal levels of CTX-II (collagen type II fragments; µg/mmol,
creatinine-corrected) in six male and six female Sprague–Dawley rats.
Error bars indicate SEM.
Table 1
Weight change after 9 weeks of treatment in female Sprague–Dawley rats (cohorts A and B) assessed in the studies of the effects
of ovariectomy on cartilage
Weight (g)
Cohort Treatment Age at start (months) n Of body at start Of body at end Of uterus at end
A OVX 5 10 292±20 370±28 ** 0.05±0.02***
Shama 5 8 295±28 324±34 0.23±0.03
B OVX 7 9 327±28 384±24 ** 0.25±0.20**
Shama 7 8 324±29 342±40 0.80±0.45
Values are means±SD. Difference between OVX and sham-operated rats were assessed using the nonparametric Mann-Whitney U test: 
aSham-operated. **P < 0.01, ***P < 0.001. OVX, ovariectomized.Knee joints were excised after termination of the experi-
ments and analyzed histologically by looking at Toluidine-
blue-stained coronal cross sections showing the femoral
and tibial condyles (Fig. 2a). The surface erosion (Fig. 2b)
was measured as the percentage of the total articular car-
tilage surface. Fig. 3 shows the Toluidine blue staining of
the articular cartilage in 7-month-old rats subjected to
either sham operation (Fig. 3a,c) or ovariectomy
(Fig. 3.b,d). The measured surface erosion is indicated by
the frame (Fig. 3b), and below is the same section shown
through a Polaroid filter (Fig. 3d), which indicates alter-
ations in the structure of the collagen fibers compared
with the intact cartilage surface (Fig. 3a) and collagen
structure (Fig. 3c) of the sham-operated rat. OVX groups
of all cohorts showed increased surface erosion in the
medial tibia, medial femur, and lateral femur compared
with the sham-operated groups. The effect of ovariectomy
on surface erosion was more pronounced in the 7-month-
old rats, particularly in the lateral femur, where differences
in comparison with the sham-operated rats reached statis-
tical significance (P = 0.009) (Fig. 4). In 7-month-old
animals, the total measure describing the severity of carti-
lage surface erosion over the four areas of interest also
indicated significantly more severe surface erosion in the
OVX group than in the sham-operated group (P = 0.008)
(Fig. 4).
When cartilage surface erosion was assessed in vehicle-
treated 5-month-old OVX rats from the intervention study
(cohort C), similar results were obtained (Fig. 5). The most
severe surface erosion of the articular cartilage was seen
in the medial and lateral femur, but the total measure was
also significantly higher in these vehicle-treated OVX
animals than in the sham-operated group (P = 0.012).
Estrogen-treated OVX animals displayed surface erosions
Available online http://arthritis-research.com/content/6/2/R169
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Table 2
Weight changes after 9 weeks of treatment in female Sprague–Dawley rats (cohort C) assessed in the study of the effect of
exogenous estrogen and SERM in ovariectomy
Weight (g)
Treatment n Of body at start Of body at end Of uterus at end
OVX, vehiclea 12 269±26 320±31 0.13±0.04
OVX, estrogen 11 273±27 296±26*  0.44±0.14***
OVX, lowb SERM 11 269±26 319±33 0.18±0.05**
OVX, highc SERM 12 268±23 287±24* 0.19±0.03***
Shamoperation, vehiclea 10 276±26 303±29 0.66±0.10***
Values are means±SD. aVehicle (50% propylene glycol, 0.075 M NaCl); bLow dose (0.2 mg/kg per day); cHigh dose (5 mg/kg per day). Difference
from the OVX group treated with vehicle only, assessed using the nonparametric Mann-Whitney U test: *P < 0.05, **P < 0.01, ***P < 0.001. OVX,
ovariectomized; SERM, selective estrogen receptor modulator ((-)-cis-3,4-7-hydroxy-3-phenyl-4-(4-(2-pyrrolidinoethoxy)phenyl)chromane).
Figure 2
Sections from the knees of 7-month-old rats subjected to ovariectomy,
stained with Toluidine blue, showing the distal femur and proximal tibia
(a,b) with the meniscus (M) to the left (a). The surface erosion is
indicated by the long, thin black bar (b). Scale bars: 200µm.
Figure 3
Knee sections, stained with Toluidine blue, showing effects of sham
operation (a,c) or ovariectomy (b,d) in 7-month-old rats. In (c) and (d),
the structure of the collagen fibers is visualized by polarized light. The
sham-operated rat (a,c) shows a healthy articular cartilage surface,
whereas the ovariectomized rat (b,d) shows surface erosion (b, framed
area) and alterations in the structure of the collagen fibers (d, framed
area). Scale bars: 200µm.similar in severity to those in the sham-operated group.
Hence, surface erosion measurements for the medial and
lateral femur, medial tibia, and total knee joint of the estro-
gen-treated group were significantly lower than for the
vehicle-treated OVX group. The two groups of SERM-
treated animals also showed less severe surface erosion.
The high-dose SERM group showed a similar incidence of
cartilage erosion to that seen in estrogen-treated rats. In
addition, the severity measurements were significantly
lower than in the medial and lateral femur, lateral tibia, and
total knee joint of the vehicle-treated group (Fig. 5). The
group treated with low doses of the SERM showed
reduced surface erosion, but the effect was not as pro-
nounced as in the high-dose group. Only the measure-
ment for the medial femur of the low-dose SERM group
was significantly lower than that in the vehicle-treated
OVX group (P = 0.018).
Bone and cartilage turnover
Bone and cartilage turnover were quantified in all rats by
measurement in serum of CTX-I and urinary measurement
of CTX-II, reflecting bone and cartilage turnover, respec-
tively. The 5-month-old cohorts had higher levels of both
markers. For CTX-I, the baseline levels were
49.2 ± 13.9 ng/ml and 26.9 ± 14.7 ng/ml in the 5- and
7-month-old rats, respectively (mean ± SD). For CTX-II, the
corresponding baseline values were 2.25 ± 0.83 and
0.85 ± 0.42 µg/mmol.
In line with the histological findings, ovariectomy induced
significantly increased CTX-II levels in all cohorts (Figs 6
and 7). The increase in CTX-II was most pronounced at
week 4 after ovariectomy, showing a decreasing tendency
thereafter. Nine weeks after ovariectomy, there was no sig-
nificant difference between CTX-II levels in the OVX and
sham-operated groups. The OVX rats treated with estro-
gen and the highest dose of SERM presented CTX-II
levels similar to those in the sham-operated group (Fig. 7).
The low dose of the SERM showed intermediate effects
on CTX-II levels.
The effect of ovariectomy on bone resorption was clearly
reflected by the elevation in serum CTX-I concentration
(Figs 6 and 7). The OVX rats treated with estrogen had
CTX-I levels similar to those in the sham-operated group
(Fig. 7). However, even the highest dose of the SERM
compound was not able to suppress bone resorption to
the same extent as estrogen, indicated by the less pro-
nounced decrease in the CTX-I marker. The animals
treated with a low dose of SERM showed even less pro-
nounced effects on CTX-I levels.
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Figure 4
Cartilage surface erosion in four condyles in 5-month-old (a) and 7-month-old (b) female rats maintained for 9weeks after ovariectomy or a sham
operation. The erosion (expressed as percentage of total cartilage surface) is presented as mean erosion+SEM for the two groups (OVX and sham-
operated). Mean scores are represented for each of the four condyles — medial tibia (Medial T), medial femur (MedialF), lateral tibia (LateralT), and
lateral femur (LateralF) — and for all four taken as a group (Total). P values indicate difference between ovariectomized (OVX) and sham-operated
rats assessed using the nonparametric Mann–Whitney U test.
Figure 5
Severity of cartilage surface erosion in knee-joint cartilage of 5-month-
old ovariectomized (OVX) rats treated with the vehicle alone (OVX
vehicle), with estrogen (OVX estrogen), or with the selective estrogen
receptor modulator (SERM) (-)-cis-3,4-diarylhydroxychromane, given in
either a low dose (0.2 mg/kg per day; OVX SERM low) or a high dose
(5 mg/kg per day; OVX SERM high). Means for vehicle-treated sham-
operated rats are also included (Sham). The erosion is expressed as
percentage of total cartilage surface. The left side of the graph shows
the accumulated total mean score for all four joint compartments
(medial and lateral femur and tibia) and the right side, for the medial
femur only. Error bars indicate SEM. The significance of differences
between treatment groups and the OVX vehicle group was assessed
using Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001.The association between bone and cartilage turnover
markers CTX-I and CTX-II was assessed in baseline
samples from the three study cohorts. The correlation
coefficients (Spearman’s rho) were between –0.04 and
–0.30 (P > 0.05), indicating that at baseline there was no
prominent association between bone and cartilage
turnover in the rats (data not shown).
Correlation between biomarkers and histology
The correlation between the severity of cartilage damage
and CTX-II or CTX-I was calculated for each study cohort
(Table 3). CTX-I levels did show significant correlation
with the surface erosion in cohorts A and B (Table 3), in
accord with the specificity of this marker for bone resorp-
tion. In cohort C, however, there was a correlation
between changes in CTX-I levels during the first 4 weeks
of treatment and subsequent erosion at termination, after
9 weeks of treatment (Table 3). This may be due to the
similarities in dynamics of the responses seen with the
CTX-I and CTX-II marker in this intervention study (Fig. 7).
Significant correlations were found between 4-week
changes in CTX-II levels and final measurements of carti-
lage surface erosion (total knee) in study cohorts B and C
(r = 0.74 and 0.50 respectively). Also, the absolute levels
of CTX-II at week 4 were significantly correlated with the
severity of cartilage surface erosion in these two studies.
In cohort A, comprising 18 5-month-old rats, there was a
correlation between CTX-II change and surface erosion,
but it did not reach statistical significance. When the four
compartments of the knee were considered individually,
the highest correlations were observed for the medial
femur (in which the highest surface erosion was seen),
where significant correlation with both absolute levels and
changes in CTX-II was found in all study cohorts (Table 3).
Significant correlations were also found for the lateral
femur.
Figure 8 depicts the association between cartilage surface
erosion and changes in CTX-II observed in cohort C. All
rats from this cohort were stratified in quartiles according
to the magnitude of change in CTX-II levels, and the
average surface erosion in each quartile was calculated.
Rats in the highest quartile (showing the largest increases
in CTX-II levels) included 11 of the 12 rats from the
vehicle-treated OVX group, and these animals showed
significantly more surface erosion than rats in the lower
quartiles. Correspondingly lowest surface erosion was
seen among the animals of the lowest quartile of CTX-II
change. The differences between the quartiles were highly
significant as assessed by analysis of variance (ANOVA)
(P = 0.001).
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Figure 6
Cartilage and bone turnover in the ovariectomized (OVX) and sham-treated (SHAM) rats. Cartilage turnover was assessed using collagen type II
fragments (CTX-II) as a marker (a,b), and bone resorption was determined by measurement of collagen type I fragments (CTX-I) (c,d).
Measurements, made at the weekly intervals shown, are from rats that were (a,c) 5 months old and (b,d) 7 months old at the beginning of the study.
Data are presented as average percentage of individual baseline, with error bars representing SEM.Body weight did not correlate with the severity of cartilage
surface erosion. The correlations (r) between terminal
body weight and articular cartilage erosion were r = 0.20,
0.21, and 0.22 (P > 0.05) for cohorts A, B and C respec-
tively, indicating that less than 5% of the apparent surface
erosion in the OVX group can be attributed to the effects
of an increased body weight (data not shown).
Discussion
Estrogen receptors are found in a wide range of cell types
in the body, explaining the pleiotropic effects of this
hormone [15]. The effect of estrogen on several estrogen-
responsive tissues such as endometrium, bone, and
breasts has been extensively studied. In the present study,
cartilage turnover and morphology were assessed in
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Table 3
Correlations between histologically assessed cartilage erosion scores and markers of bone (CTX-I) and cartilage (CTX-II) turnover
in the knees of female Sprague–Dawley rats
Changes in CTX-I Changes in CTX-II
Age at start From From
Cohorta (treatment) (months) weeks 0–4 At week 4 weeks 0–4 At week 4
A (OVX or shamb) (n = 18) 5
Cartilage erosion: Total 0.10 0.15 0.50 0.27
Medial femur 0.47 –0.02 0.64* 0.51*
B (OVX or shamb) (n = 17) 7
Cartilage erosion: Total 0.24 0.25 0.74** 0.54*
Medial femur 0.24 0.41 0.70** 0.63**
C (OVX + intervention or shamb) (n = 56) 5
Cartilage erosion: Total 0.40** 0.34* 0.50*** 0.43**
Medial femur 0.35* 0.33* 0.37** 0.45**
Values are Spearman’s rho. aCohorts: A, see Table 1; B, see Table 1; C, intervention with either estrogen or SERM – see Table 2. bSham
operation. *P < 0.05, **P < 0.01, ***P < 0.001. CTX-I, collagen type I fragments; CTX-II, collagen type II fragments.
Figure 7
Bone and cartilage turnover in 5-month-old ovariectomized (OVX) rats treated with vehicle alone (OVX vehicle), estrogen (OVX estrogen), or the
selective estrogen receptor modulator (SERM) (-)-cis-3,4-diarylhydroxychromane, given in either a low dose (0.2 mg/kg per day; OVX SERM low)
or a high dose (5 mg/kg per day; OVX SERM high). Values for vehicle-treated sham-operated rats (Sham) are also included. Bone resorption was
determined by measurement of collagen type I fragments (CTX-I) (a), and cartilage turnover was assessed using collagen type II fragments (CTX-II)
as a marker (b). Measurements were made at the weekly intervals shown, starting when the rats were 5 months old. The significance of differences
between groups was assessed by nonparametric analysis of variance (ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001.sham-operated and OVX rats to investigate whether ces-
sation of endogenous estrogen production may influence
articular cartilage turnover and integrity. Our findings show
that ovariectomy induces a significant increase in the
breakdown of collagen type II and subsequent articular
cartilage erosion. Furthermore, we demonstrate that
administration of exogenous estrogen or a SERM to OVX
rats suppresses the progression of these events.
The assessment of articular cartilage turnover in rodents is
complicated by the fact that the growth plate in these
animals remains present and is at least partly metabolically
active, even at older age [16]. The growth plate contains a
significant amount of collagen type II, which undergoes
constant remodeling during ectopic bone formation and
thereby contributes to systemic levels of collagen type II
metabolites [17]. Accordingly, we observed high CTX-II
levels in animals below 3 months of age (Fig. 1), suggest-
ing that a significant fraction of the analytes obtained from
young rats and measured in the assay originates from
growth plate turnover and not from articular cartilage. A
similar situation is observed in humans younger than 20 to
25 years of age, but in contrast to the situation in rodents,
the growth plates in human adults close when skeletal
growth has ceased [18]. In 6-month-old rats, the CTX-II
levels decreased by 86% compared to 3-month-old rats
(Fig. 1), suggesting that skeletal growth and thereby
growth-plate turnover at this time are minimized. These
observations formed the rationale for assessing the effects
of ovariectomy on cartilage turnover and structural
integrity in 5- and 7-month-old rats.
In OVX rats from all three cohorts, an increase in the
degree of cartilage erosion of the hind knee joints was
observed at termination of the study, after 9 weeks of
treatment. The OVX rats had a significantly higher inci-
dence of cartilage surface erosion in the medial tibia and
lateral femur than the sham-operated rats. This tendency
was also found in the medial femur, but the lateral tibia
showed no difference between OVX and sham-operated
animals in any of the assessed cohorts. The rats of
cohorts B and C showed a more pronounced erosive
change to ovariectomy. However, the changes were most
pronounced in the femoral condyles in all experiments,
suggesting that the relative responses of the different
regions of the knee joint are similar at these two ages.
The pathological changes observed in the OVX rats were
of a similar nature to the very early changes observed in
human OA, where mild erosion and loss of proteglycans
are among the earliest changes that have been described
[19,20]. The histological appearance of the knee articular
cartilage in the OVX group differs from the appearance of
articular cartilage in models such as ligament transection
and meniscal tear [2,5]. In these models, more severe
erosive changes can often be observed and changes such
as fibrillation and vascularization appear markedly
increased. The changes in knee cartilage observed after
ovariectomy were relatively mild in comparison and may
represent features of earlier or less aggressive disease,
which are stages of the disease that are difficult to
address in many of the currently used models of OA. Thus,
the OVX model may be uniquely suitable for the study of
early-stage OA.
A significant elevation in CTX-I levels reflecting bone
resorption was observed in the OVX rats in comparison
with the sham-operated group. This observation is in
accord with the expected increase in bone turnover
induced by ovariectomy [21; P Qvist and colleagues,
unpublished]. The dynamics of the changes in CTX-I levels
over the 9-week study period suggests a sustained
increase of approximately 100% in OVX rats compared
with the sham-operated group (Fig. 6). This increase is
similar in magnitude to that seen in bone turnover at the
menopause transition [22]. These observations indicate
that ovariectomy in rats induces estrogen deficiency that
can evoke the skeletal metabolic changes typically accom-
panying the menopause. These observations are in accord
with findings from other studies [12,15,21; P Qvist and
colleagues, unpublished]. Also, the observed increase in
body weight and decrease in uterus weight observed in all
cohorts as a consequence of ovariectomy is in agreement
with the known systemic effects of estrogen withdrawal
[15].
Cartilage turnover as assessed by the CTX-II assay was
also increased in the OVX rats compared with the sham-
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Figure 8
Association between cartilage surface erosion (score for total knee)
and collagen type II degradation products (CTX-II). Rats from all
treatment groups in cohort C (see text and Table 2) were stratified
according to CTX-II change after 4 weeks and the average surface
erosion for each quartile (Q) is presented. Error bars indicate SEM.
P = 0.001 by nonparametric analysis of variance (ANOVA).operated group. The difference was most pronounced in
the first 4 to 6 weeks after ovariectomy, where CTX-II
levels were increased by 100%, but at later time points
the difference between the OVX and sham-operated
animals were diminished. This observation suggests that
the increase in cartilage turnover induced by cessation of
endogenous estrogen production may be transient in the
OVX model, possibly reflecting the activation of mecha-
nisms antedating the actual cartilage damage. The initial
increases in the levels of the marker observed immediately
after ovariectomy corresponded well with the increase in
CTX-II levels observed at the menopause in humans,
where a 100% increase has been demonstrated [18]. We
have analyzed animals up to 15 weeks after ovariectomy,
in which surface erosions were present to the same extent
as seen in the rats maintained for 9 weeks. Whether the
surface erosions posses the ability to spontaneously
repair after longer times cannot be determined from our
studies.
The changes in the cartilage turnover marker (CTX-II)
observed after 4 weeks showed close correlation with the
histological signs of articular cartilage degradation
observed at study termination (Table 2; Fig. 5). Thus, the
early changes in the biomarker levels can be considered
predictive of the subsequent structural changes in the
knee joint. This is in accordance with findings obtained in
clinical investigations, where CTX-II levels and changes in
this marker are correlated with radiologically assessed
damage of articular cartilage in the knee joint [23–25].
The menopause can frequently be accompanied by an
increase in body weight, which can partly be ascribed to
estrogen deficiency. Increased body weight, especially fat
accumulation, may theoretically have an inhibitory effect
on articular cartilage degradation through increased pro-
duction of endogenous estrogens. Increases in body
weight may also enhance cartilage degradation evoked by
a greater physical challenge of the joints. In the present
study, we observed a significant weight gain in OVX rats.
However, there was no correlation between body weight
and cartilage erosion, suggesting that the observed histo-
logical changes of knee articular cartilage in OVX rats is
unlikely to be a result of increased body weight and is
more likely to be due to estrogen deficiency per se. This
observation is also supported by a previous study on
healthy humans indicating an apparently minor overall con-
tribution of body weight to cartilage turnover as assessed
by the CTX-II assay [18].
In the present study, we also investigated whether exoge-
nous estrogen and an estrogen-like substance can
provide prophylactic effects against the acceleration of
cartilage degradation associated with ovariectomy. These
hypothesized effects were investigated with reference to
the well-known effects of these agents on bone turnover
[12,26,27]. Furthermore, it has also been demonstrated
that the SERM idoxifene reduces disease severity and
bone erosion in adjuvant-induced arthritis, an animal
model of RA [28]. We tested a SERM belonging to the
class of cis-3,4-diaryl-chromanes, which have been
demonstrated to provide significant antiresorptive effect in
OVX rat studies [12]. The SERM is structurally very similar
to levormeloxifene, which has been tested clinically in
postmenopausal women and found to be more potent
than hormone replacement therapy in preventing bone
loss [27].
The levels of CTX-II in OVX rats treated with the higher
dose of the SERM or with estrogen were similar to levels
seen in the sham-operated animals of the same cohort. In
contrast, the lower dose of SERM was only partly effective
in reducing the elevated CTX-II levels. For CTX-I levels,
only estradiol treatment was able to completely suppress
bone resorption to levels seen in the sham-operated rats,
whereas the two SERM-treated groups showed an inter-
mediate effect. In accord with the effects observed with
the biomarkers, the histological examination revealed that
whereas the vehicle-treated OVX rats again showed sig-
nificantly increased erosions of the cartilage surface, the
groups treated with estrogen or SERM were indistinguish-
able from the vehicle-treated sham-operated group. The
SERM showed a dose-dependent ability to prevent the
erosive changes. There was a high correlation between
changes in CTX-II observed in the first 4 weeks of the study
period and subsequent erosion of articular knee cartilage.
The three sets of separate experiments described here
were all in line with significantly increased cartilage
erosion in OVX rats, pointing to an apparent chondropro-
tective influence of endogenous estrogen on cartilage
turnover. Furthermore, administration of exogenous estro-
gen to OVX rats prevented the erosive changes, thereby
further supporting the association between estrogen and
cartilage. These observations are in accord with findings
from previous studies indicating that the prevalence and
incidence of OA is increased among postmenopausal
women [11,29]. The notion that cartilage metabolism may
be influenced by estrogen is conceivable also, because
chondrocytes of articular cartilage possess functional
estrogen receptors [15,30,31]. Recent publications
describing the results of a 3-year follow-up study of
ovariectomized cynomolgus monkeys have provided
strong evidence that ovariectomy induces OA-like
changes in articular cartilage [9]. In this animal model,
administration of exogenous estrogens, but not phyto-
estrogens, was able to prevent these changes. A similar
indication of potential chondroprotective properties of
estrogen has been obtained in several epidemiological
and case–control studies, where estrogen use in
menopausal women has been associated with a
decreased incidence of OA [7,32]. CTX-II levels are
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hormone replacement therapy can suppress this marker to
premenopausal levels, further supporting a role of estro-
gen as a regulator of cartilage metabolism [18]. Based on
these previous observations, it seems reasonable to con-
sider the model of older OVX rats (i.e. 5 months of age or
more) as an in vivo model of postmenopausal OA.
However, the ultimate demonstration of the utility of the
model awaits the introduction of novel agents with poten-
tial chondroprotective effects.
Conclusion
The present study further supports the role of endogenous
estrogens in the regulation of articular cartilage turnover
and preservation of joint integrity. In addition, the results
suggest that the adapted OVX model described here has
potential as a useful in vivo model for the clinical assess-
ment of chondroprotective effects of novel therapeutic
compounds.
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